San Diego Business Journal

Isis Pharmaceuticals Inc. announced Monday that it has earned a $15 million milestone payment from GlaxoSmithKline Plc.

The milestone comes from advancing the Phase 2/3 study of antisense drug candidate ISIS-TTRRx in patients with familial amyloid polyneuropathy.

Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.